Better Therapeutics (Better Therapeutics) Cash-to-Debt : 0.46 (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Better Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Better Therapeutics's cash to debt ratio for the quarter that ended in Sep. 2023 was 0.46.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Better Therapeutics couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Better Therapeutics's Cash-to-Debt or its related term are showing as below:

BTTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.15 Med: 1.28 Max: No Debt
Current: 0.46

During the past 4 years, Better Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.15. And the median was 1.28.

BTTX's Cash-to-Debt is ranked worse than
85.84% of 1540 companies
in the Biotechnology industry
Industry Median: 6.525 vs BTTX: 0.46

Better Therapeutics Cash-to-Debt Historical Data

The historical data trend for Better Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Better Therapeutics Cash-to-Debt Chart

Better Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Cash-to-Debt

0.15

0.19

4.27

1.06

Better Therapeutics Quarterly Data
	Dec19	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial									1.51	1.06	0.42	0.44	0.46

Competitive Comparison of Better Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Better Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Better Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Better Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Better Therapeutics's Cash-to-Debt falls into.

Better Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Better Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	15.74	/	(4.532	+	10.348)
	=	1.06

Better Therapeutics's Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	6.598	/	(6.586	+	7.721)
	=	0.46

Better Therapeutics (OTCPK:BTTX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Better Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Better Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Better Therapeutics (Better Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Better Therapeutics Inc (OTCPK:BTTX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

548 Market Street, Suite 49404, San Francisco, CA, USA, 94104

Website

https://www.bettertx.com

Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases. The company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for type 2 diabetes, heart disease and other conditions.

Executives

Elder Granger	director	5176 S. LEWISTON WAY, CENTENNIAL CO 80015
Mark A. Berman	officer: Chief Medical Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Geoffrey M. Parker	director	15 RIORDAN PLACE, MENLO PARK CA 94025
Frank Karbe	director, officer: See Remarks	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
David P Perry	director, 10 percent owner, officer: See Remarks	1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Andrew J. Armanino	director	C/O CALIFORNIA BANCORP, 1300 CLAY STREET, FIFTH FLOOR, OAKLAND CA 94612
Georgianna Maule-ffinch 2015 Trust	10 percent owner	C/O BETTER THERAPEUTICS, INC., 548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Mark Heinen	officer: See Remarks	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Risa J Lavizzo-mourey	director	GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE ST., CHICAGO IL 60661
Kevin J Appelbaum	director, 10 percent owner, officer: Chief Executive Officer	4160 DUBLIN BLVD., SUITE 200, DUBLIN CA 94568
Suying Liu	director	311 WEST 43RD STREET, 12TH FLOOR, NEW YORK NY 10036
Justin Zamirowski	officer: Chief Commercial Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Kristin Wynholds	officer: Chief Product Officer	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104
Richard H Carmona	director	1221 BROADWAY, OAKLAND CA 94612
David P. Perry 2015 Trust	10 percent owner	548 MARKET STREET, #49404, SAN FRANCISCO CA 94104